Personalized immune cell vaccine for multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests an experimental vaccine made from your own immune cells (dendritic cells) to help your body fight multiple myeloma. It is for people whose cancer is already in very good remission after previous treatments, with the goal of keeping it from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have multiple myeloma or a related plasma cell tumor (plasmacytoma).
- Your cancer must have responded very well to previous treatments (very good partial response or complete remission).
- You must be expected to live for at least 3 more months (12 weeks).
- You must be able to have blood drawn or participate in apheresis (a procedure to collect blood cells).
- You cannot be pregnant or breastfeeding.
- You must not have an uncontrolled active infection, HIV, or active hepatitis B or C.
- You cannot be taking systemic steroids (steroid pills or injections), but inhaled steroids (for asthma) are allowed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized vaccine made from your own immune cells (dendritic cells) to help your body fight advanced cancer. It is for people whose cancer has not responded to other treatments.
This trial tests a new cell therapy (O&D-001) for multiple myeloma that has returned or not responded to previous treatments. It targets specific markers on myeloma cells (BCMA or GPRC5D) and aims to shrink the cancer.
This trial tests a personalized vaccine made from your own immune cells (a dendritic cell vaccine) that may help your body fight the brain tumor. It is meant for people with DIPG or glioblastoma who have already tried standard treatments but still have tumors.
This trial tests a personalized vaccine made from your own immune cells (dendritic cells) mixed with myeloma cells, given together with a drug called elranatamab. It is for people with multiple myeloma that has not responded to at least three prior treatments.
This trial tests whether a personalized vaccine (DC/MM fusion) given after standard CAR-T cell therapy can help prevent the cancer from coming back. It is for people with multiple myeloma that has returned or not responded to treatment.
This trial is testing a new cell therapy (called Eque-cel) for people with multiple myeloma that has come back or stopped responding to standard treatments. The therapy uses your own immune cells to attack the myeloma cells. You may qualify if you've tried at least three prior treatment combinations.
Hear when a new Multiple Myeloma or Plasmacytoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.